Demonstrating Biosimilarity - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Demonstrating Biosimilarity
Extensive comparability testing is required to ensure that biosimilars have comparable profiles to their reference products.

Pharmaceutical Technology
Volume 37, Issue 8, pp. 42-45

Comparability studies
Small changes in the manufacturing process can alter a product's efficacy and safety. According to the guidelines of the EMA, extensive comparability testing will be required to demonstrate that the biosimilar has a comparable profile in terms of quality, safety and efficacy as the reference product.

Various analytical assays are available to compare physicochemical and biological properties between production batches of a biosimilar in comparison with a reference product. It is important to recognize the limits of existing assays so that the results can be accurately interpreted for marketing authorization. It is also important to have careful interpretation of results to ensure continued safety and efficacy in the target populations. Analytical assays, therefore, have an important role in the decision-making process for marketing authorization of biosimilar products.

Demonstrating equivalence to the materials used in toxicology and early phase clinical trials are required if bridging studies are to be avoided. Yet, demonstrating that two separate manufactured lots are identical is very difficult. The key is to achieve a level of consistency that falls within a set of defined parameters based on testing and characterization.

Prior knowledge of the innovator product (i.e., biochemical, biological, and clinical data) is principally held by the regulatory authorities based on historical filing of clinical and toxicology data. The ability to reduce development time for the sponsor of the biosimilar is based on good regulatory interaction at the earliest stage of manufacture. This is important as such additional studies (e.g., bridging studies) can significantly extend development timelines and the cost of biosimilar development. Successful and effective comparability studies are thus key in the development of biosimilars.

Chemical analysis. As with small-molecule generic drugs, the structure of the biosimilar must be analyzed but unlike small molecules, it is not so much a black-and-white question of proving that it is exactly the same but rather proving that it is sufficiently close to resulting in no obvious or appreciable functional difference in its biological activity. Analytical characterization of a biosimilar should include primary, secondary, tertiary, and quaternary structural assessment, biological activity and analysis of product impurities. All of these components must be understood and further characterized during comparability studies of the biosimilar with reference to the innovator drug. Molecular weight is assessed using one or more forms of mass spectrometry, usually matrix-assisted laser desorption/ionization mass spectrometry (MALDI–MS), electrospray MS or liquid chromatography–mass spectrometry (LC–MS). Techniques such as sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE), high-performance liquid chromatography (HPLC), peptide mapping, glycosylation patterns, amino acid determination, and carbohydrate content analysis are also used to carry out isoform and impurity studies.

There is no single analytical technique that will demonstrate all required criteria and characteristics of a biosimilar product for the purposes of comparison; therefore, a wide variety of tools are needed for this purpose. Several examples of these techniques are defined below:

  • Mass spectrometry can be utilized to show any differences in molecular shift between the biosimilar and innovator product
  • Capillary isoelectric focusing (cIEF) can be used to provide data for in-process samples
  • Biacore analysis is used to assess receptor binding function
  • Peptide mapping is utilized to differentiate enzymes or combinations of enzymes.

Biological analysis. Biologically relevant tests must be used to measure the product's activity and can also be used to glean information about higher order protein structure. In all instances, the results are compared with those of similar analyses for the reference innovator product. It is, however, not expected that the quality attributes of the biosimilar and the reference product will be completely identical. Minor structural differences between the two active substances may potentially be acceptable, but must be justified, as must any variability in post-translational modifications and differences between the impurity profiles. These differences will only be deemed acceptable if they are supported by the comparability exercise for quality attributes in relation to safety and efficacy.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here